A powerful drug derived from marijuana just got a major green light on its way to FDA approval
- An experimental cannabis-derived drug has gotten a unanimous approval vote today from a group of scientists convened by the Food and Drug Administration.
- The committee concluded that the drug, called Epidiolex, is safe and effective.
- That vote will play a key role in the FDA's final approval decision, which is scheduled for June 27.
- Epidiolex is made by GW Pharmaceuticals and is designed to treat two rare forms of epilepsy using cannabidiol, or CBD.
An experimental drug derived from cannabis to treat epilepsy is on the brink of becoming the first of its kind to win US government approval.
On Thursday, a panel of outside experts convened by the Food and Drug Administration voted unanimously in favor of the drug's safety and effectiveness. Their recommendation will play a key role in the FDA's approval decision for the drug, which is made by GW Pharmaceuticals.See the rest of the story at Business Insider
NOW WATCH: Why humans enjoy pain so much
See Also:
- A $22 billion investment firm led one of the largest ever funding rounds for a cannabis tech company — here's why it's a big deal for the industry
- Ketamine could become the first new depression drug in more than 30 years
- A world-record holder who runs 100-mile races says the high-fat diet Silicon Valley loves transformed his body and performance
SEE ALSO: Pharmaceutical giants are sidestepping US marijuana restrictions to research cannabis-based drugs